Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal antibodies Company now expects to end 2024 with at least $75 million in cash and cash equivalents, an update to previously issued financial guidance WALTHAM, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to protection from serious viral infectious diseases, today announced that fol ...